Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$58 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-103 Mln
ROE
-0.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.2
Industry P/E
--
EV/EBITDA
0.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-4.2
Face value
--
Shares outstanding
39,261,700
CFO
$-321.36 Mln
EBITDA
$-350.46 Mln
Net Profit
$-413.59 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Tcr2 Therapeutics Inc (TCRR)
| 48.1 | -16.1 | 18.4 | -36.2 | -47.3 | -- | -- |
|
BSE Sensex*
| -8.4 | -1.7 | -8.7 | 6.1 | 9.0 | 9.3 | 12.1 |
|
Company
|
2022
|
2021
|
2020
|
|---|---|---|---|
|
Tcr2 Therapeutics Inc (TCRR)
| -78.6 | -84.9 | 116.6 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Tcr2 Therapeutics Inc (TCRR)
|
1.5 | 58.1 | 0.0 | -163.1 | -- | -111.5 | -- | 0.2 |
| 64.4 | 8,558.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 38.2 | 15.0 | |
| 65.8 | 7,998.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.5 | |
| 44.2 | 11,791.6 | 2,320.1 | 782.6 | 39.0 | 35.5 | 15.8 | 5.3 | |
| 92.8 | 11,760.7 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.4 | 7,473.4 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.6 | 156.5 | |
| 519.8 | 12,247.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.8 | |
| 520.7 | 14,077.1 | 2,530.2 | 451.1 | 21.3 | 70.2 | 32.5 | 30.8 | |
| 105.0 | 8,153.4 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 320.2 | 8,644.3 | 0.0 | -303.3 | -- | -45.8 | -- | 10.1 |
TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. Its lead product candidate is gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells)... targeting mesothelin-expressing solid tumors, which is in Phase 1/2 clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma and acute myeloid leukemia. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Read more
Pres, CEO & Director
Dr. Garry E. Menzel M.B.A., Ph.D.
Pres, CEO & Director
Dr. Garry E. Menzel M.B.A., Ph.D.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Tcr2 Therapeutics Inc (TCRR) is $1.48 (NASDAQ) as of 01-Jun-2023 09:30 EDT. Tcr2 Therapeutics Inc (TCRR) has given a return of -47.28% in the last 3 years.
Since, TTM earnings of Tcr2 Therapeutics Inc (TCRR) is negative, P/E ratio is not available.
The P/B ratio of Tcr2 Therapeutics Inc (TCRR) is 0.22 times as on 01-Jun-2023, a 95 discount to its peers’ median range of 4.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.26
|
0.28
|
|
2021
|
-1.77
|
0.63
|
|
2020
|
-12.90
|
3.66
|
|
2019
|
-6.30
|
1.87
|
|
2018
|
--
|
--
|
The 52-week high and low of Tcr2 Therapeutics Inc (TCRR) are Rs -- and Rs -- as of 09-Apr-2026.
Tcr2 Therapeutics Inc (TCRR) has a market capitalisation of $ 58 Mln as on 01-Jun-2023. As per SEBI classification, it is a company.
Before investing in Tcr2 Therapeutics Inc (TCRR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.